It’s been a while since I last posted. My latest project has been taking up my free time – I’m working on an online crowd-sourced research database for those with metastatic breast cancer. Many of us involved in the breast cancer world are too familiar with the shortcomings of clinical research. It takes too long [...]
by Gwen on February 10, 2012
Please see my original post on everolimus here Today, the prestigous New England Journal of Medicine published results of the eagerly anticipated BOLERO 2 clinical trial[1]. It showed that adding everolimus (brand name Afinitor) to exemestane (brand name Aromasin, an aromatase inhibitor) greatly improved outcomes for women with metastatic and advanced hormone-positive (ER+ and/or [...]
by Gwen on January 24, 2012
You can find an overview of the most important presentations of the 2011 San Antonio Breast Cancer Symposium here. A couple of weeks ago, a client of mine was diagnosed with ER-positive, HER2-negative breast cancer. At the time of our consultation, I could not find the report that gave any details – only that she [...]
by Gwen on January 24, 2012
You can find an overview of the most important presentations of the 2011 San Antonio Breast Cancer Symposium here. #P1-08-12 by T I Barron and others First comes the diagnosis of breast cancer. Then comes the cancer surgery. This is often followed by grueling chemotherapy or radiation protocols. Just when you’re about to declare victory [...]
by Gwen on January 8, 2012
You can find an overview of the most important presentations of the 2011 San Antonio Breast Cancer Symposium here. Poster #4-07-07 by A. Lucci and others. For a while now, we have seen how a simple blood test that measures circulating tumor cells (CTCs) can predict response to treatments for metastatic breast cancer. Now we [...]
This site complies with the HONcode standard for trustworthy health information: 